• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [21959 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Systematic review about effectiveness of digital pathology as a diagnostic tool for pathology and cytopathology]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Coping strategies in complex medical situations - the example of coronary heart disease]
2021     NIHR Health Services and Delivery Research programme Models of generalist and specialist care in smaller acute hospitals: an exploratory study
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: noninvasive fetal RhD genotyping using maternal plasma]
2021     Scottish Health Technologies Group (SHTG) Detection of paroxysmal atrial fibrillation in patients with newly diagnosed ischaemic stroke
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Autologous anti-CD19-transduced CD3+ cells (mantle cell lymphoma, pretreated patients)]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice ravulizumab (Ultomiris®) for the treatment of PNH and aHUS
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab (follicular lymphoma, first line) - Benefit assessment according to §35a Social Code Book V]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [The potential influence of socio-demographical factors on access to and results of rehabilitation]
2021     The Federal Joint Committee (G-BA) [Pharamceutical Directive/Annex XII: Avapritinib (gastrointestinal stromal tumours)]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice tirbanibulin (Klisyri®) for the treatment of adults with actinic keratosis
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tucatinib (breast cancer) - Addendum to Commission A21-26]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice venetoclax (Venclyxto®)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lanadelumab (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V]
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Stereotactic ablative radiotherapy for the treatment of oligometastatic cancer: a clinical review as part of a health technology assessment v1.0
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment ponesimod (Ponvory®) for the treatment of relapsing forms of multiple sclerosis (RMS)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional supplementation in acute pancreatitis]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Speech therapy for aphasia]
2021     Swiss Federal Office of Public Health (FOPH) Statins in the primary prevention of cardiovascular events and mortality in Switzerland
2021     NIHR Health Technology Assessment programme Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: microbiological stool testing in adults and children with diarrhea: relevance and measures to promote judicious use]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice cemiplimab (Libtayo®) for the treatment of non-small cell lung carcinoma (NSCLC)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (Hodgkin lymphoma) - Addendum to Commission A21-35]
2021     Swiss Federal Office of Public Health (FOPH) Vertebroplasty or kyphoplasty in painful osteoporotic vertebral compression fractures unresponsive to non-surgical treatment
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: pertussis - diagnostic modalities and trajectory]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment empagliflozin (Jardiance®) for the treatment of adults with chronic heart failure
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avatrombopag (thrombocytopenia) - Addendum to Commission A21-31]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS review levomepromazine (Nozinan®) for palliative sedation in a home situation
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (colorectal cancer) - Addendum to Commission A21-36]
2021     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Efficacy and safety of yoga on selected clinical conditions]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Extension of further conditions for SGLT2 inhibitors following recent GVS advice (22 June 2021)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (melanoma, adjuvant) - Addendum to Commission A21-39]
2021     Swiss Federal Office of Public Health (FOPH) Chondroitin sulfate in osteoarthritis
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice CGRP inhibitors erenumab, fremanezumab, galcanezumab (Aimovig®, AJOVY®, Emgality®) for the treatment of patients with episodic and chronic migraine
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Microvascular reperfusion after percutaneous coronary intervention for acute anterior myocardial infarction - Addendum to commission H20-01]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice roxadustat (Evrenzo®) for the treatment of symptomatic anaemia in chronic kidney damage
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cenobamate (epilepsy) - Benefit assessment according to §35a Social Code Book]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatment for postpartum psychiatric disorders - an evidence map]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice drospirenon-estetrol (Drovelis®)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, gating mutation, heterozygous) - Benefit assessment according to §35a Social Code Book]
2021     Adelaide Health Technology Assessment (AHTA) Small gene panel testing for non-small cell lung carcinoma
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Follow-up advice on conditional inclusion of larotrectinib (Vitrakvi®)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, residual function mutation) - Benefit assessment according to §35a Social Code Book]
2021     Adelaide Health Technology Assessment (AHTA) Whole genome sequencing of antimicrobial-resistant pathogens
2021     Malaysian Health Technology Assessment (MaHTAS) Platelet rich plasma, platele-rich fibrin (PRF) and concentrated growth factor (CGF) for treatment of periodontal disease
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Follow-up advice on conditional inclusion of entrectinib (Rozlytrek®)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, gating mutation, heterozygous) - Benefit assessment according to §35a Social Code Book]
2021     Adelaide Health Technology Assessment (AHTA) Genetic testing for childhood hearing impairment
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Identification of factors influencing the risk of absconding in a user with an intellectual disability, autism spectrum disorder or a mental health disorder]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, residual function mutation) - Benefit assessment according to §35a Social Code Book]
2021     The Regional Health Technology Assessment Centre (HTA-centrum) Clinical effects of preoperative i.v. iron infusion in patients with colorectal cancer and iron-deficiency anemia
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Perioperative antibiotics for prevention of infections in arterial reconstructions with vascular prostheses]
2021     NIHR Health Technology Assessment programme DRAFFT 2: Distal Radius Acute Fracture Fixation Trial 2
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Evaluation of the service offer from the Centre d'expertise pour les victimes de brûlures graves de l'est du Québec (CEVBGEQ) in relation to the use of pressure garments to treat scarring in severe burn patients]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice on the reassessment of tafamidis (Vyndaqel®)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V]
2021     The Regional Health Technology Assessment Centre (HTA-centrum) Clopidogrel versus ticagrelor as part of dual antiplatelet therapy for patients with acute coronary syndrome
2021     Penn Medicine Center for Evidence-based Practice (CEP) Venous irritation resulting from IV fosaprepitant
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Advice on the reassessment of axicabtagene ciloleucel (Yescarta®)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2021     The Regional Health Technology Assessment Centre (HTA-centrum) Efficacy and safety of endovascular versus surgical arteriovenous fistula creation for hemodialysis
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: artificial intelligence-assisted diabetic retinopathy tele-screening]
2021     Penn Medicine Center for Evidence-based Practice (CEP) Oral hygiene interventions to prevent ventilator-associated pneumonia (VAP)
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice on ferrimaltol (Feraccru®) for treating iron deficiency
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021     The Regional Health Technology Assessment Centre (HTA-centrum) Effectiveness and safety of breast reduction surgery, compared with no surgery, in women with symptomatic breast hypertrophy
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice on subcutaneous buprenorphine (Buvidal®)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 12 years and older, diverse mutations) - Benefit assessment according to §35a Social Code Book]
2021     Malaysian Health Technology Assessment (MaHTAS) Driving simulator in healthcare
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 12 years and older, diverse mutations) - Benefit assessment according to §35a Social Code Book]
2021     NIHR Health Technology Assessment programme Intratumoural immune signature to identify patients with primary colorectal cancer who do not require follow-up after resection: an observational study
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice for the lock procedure drug betibeglogene autotemcel (Zynteglo®)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tagraxofusp (blastic plasmacytoid dendritic cell neoplasm) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     NIHR Health Technology Assessment programme The Prognosis in Palliative care Study II (PiPS2)
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice on avelumab (Bavencio®) for treating urothelial cell carcinoma
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Feasibility of a RCT of techniques for managing an impacted fetal head during emergency caesarean section: the MIDAS scoping study
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Cabozantinib (reassessment after the deadline: thyroid carcinoma)]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice on entrectinib (Rozlytrek®) for the treatment of ROS1 fusion-positive advanced non-small cell lung cancer
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Berotralstat (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Key items for developing and implementing a high complexity/cost surgical implants registry for its postmarketing surveillance]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [National expert standards in nursing care]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Brentuximab Vedotin (reassessment after the deadline: systemic anaplastic large cell lymphoma; first-line; combination with Cyclophosphamide, Doxorubicin, and Prednisone)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Nutritional therapy in heart failure patients with malnutrition]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice for cladribine (Mavenclad®) – extension of further conditions
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ponesimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of calcifediol (Hidroferol®)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV) - Addendum to commission A20-61]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Automated storage and dispensing medication systems in hospital pharmacy services. Safety, effectiveness and efficiency]
2021     NIHR Health Technology Assessment programme Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation
2021     Malaysian Health Technology Assessment (MaHTAS) Delirium unit in geriatric ward
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice niraparib (Zejula®)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon catheter for the transurethral treatment of urethral strictures - Second addendum to commission H20-02]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of mHealth-based technology for mobile applications]
2021     NIHR Health Technology Assessment programme Fall prevention interventions in primary care to reduce fractures and falls in people aged 70 years and over: the PreFIT three-arm cluster RCT
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice SGLT-2 inhibitors
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of stereotactic radiosurgery (SRS) for the treatment of vestibular schwannoma requiring intervention]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Nutritional treatment of multi-morbid patients in a state of malnutrition]